nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—NISCH—Hypothetical Network for Drug Addiction—DRD4—Gilles de la Tourette syndrome	0.0782	0.0885	CbGpPWpGaD
Phentolamine—NISCH—Hypothetical Network for Drug Addiction—DRD2—Gilles de la Tourette syndrome	0.0729	0.0824	CbGpPWpGaD
Phentolamine—ADRA1D—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0161	0.0183	CbGpPWpGaD
Phentolamine—ADRA2B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0146	0.0165	CbGpPWpGaD
Phentolamine—ADRA1D—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0138	0.0156	CbGpPWpGaD
Phentolamine—ADRA2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0136	0.0154	CbGpPWpGaD
Phentolamine—ADRA1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0134	0.0152	CbGpPWpGaD
Phentolamine—ADRA1D—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0134	0.0151	CbGpPWpGaD
Phentolamine—ADRA1D—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0124	0.0141	CbGpPWpGaD
Phentolamine—ADRA2B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0124	0.0141	CbGpPWpGaD
Phentolamine—ADRA2B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0121	0.0136	CbGpPWpGaD
Phentolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0119	0.0135	CbGpPWpGaD
Phentolamine—ADRA2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0116	0.0131	CbGpPWpGaD
Phentolamine—ADRA1D—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0116	0.0131	CbGpPWpGaD
Phentolamine—NISCH—midbrain—Gilles de la Tourette syndrome	0.0115	0.099	CbGeAlD
Phentolamine—ADRA1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0114	0.0129	CbGpPWpGaD
Phentolamine—ADRA2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0113	0.0127	CbGpPWpGaD
Phentolamine—ADRA2B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0112	0.0127	CbGpPWpGaD
Phentolamine—ADRA1D—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0112	0.0127	CbGpPWpGaD
Phentolamine—ADRA1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0111	0.0125	CbGpPWpGaD
Phentolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0111	0.0125	CbGpPWpGaD
Phentolamine—ADRA2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0105	0.0119	CbGpPWpGaD
Phentolamine—ADRA1D—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0105	0.0118	CbGpPWpGaD
Phentolamine—ADRA2B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0104	0.0118	CbGpPWpGaD
Phentolamine—ADRA1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0103	0.0117	CbGpPWpGaD
Phentolamine—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0101	0.0115	CbGpPWpGaD
Phentolamine—ADRA2B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0101	0.0115	CbGpPWpGaD
Phentolamine—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00985	0.0111	CbGpPWpGaD
Phentolamine—ADRA2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00976	0.011	CbGpPWpGaD
Phentolamine—ADRA1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0096	0.0109	CbGpPWpGaD
Phentolamine—ADRA2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00947	0.0107	CbGpPWpGaD
Phentolamine—ADRA2B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00945	0.0107	CbGpPWpGaD
Phentolamine—ADRA2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00943	0.0107	CbGpPWpGaD
Phentolamine—ADRA1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00932	0.0105	CbGpPWpGaD
Phentolamine—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00918	0.0104	CbGpPWpGaD
Phentolamine—ADRA2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00915	0.0104	CbGpPWpGaD
Phentolamine—ADRA2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00882	0.00998	CbGpPWpGaD
Phentolamine—ADRA1D—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00872	0.00986	CbGpPWpGaD
Phentolamine—ADRA1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00868	0.00982	CbGpPWpGaD
Phentolamine—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00853	0.00965	CbGpPWpGaD
Phentolamine—ADRA2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00853	0.00965	CbGpPWpGaD
Phentolamine—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00828	0.00937	CbGpPWpGaD
Phentolamine—ADRA1B—nervous system—Gilles de la Tourette syndrome	0.00806	0.0695	CbGeAlD
Phentolamine—ADRA2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00792	0.00897	CbGpPWpGaD
Phentolamine—ADRA1D—nervous system—Gilles de la Tourette syndrome	0.00789	0.068	CbGeAlD
Phentolamine—ADRA2B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00787	0.0089	CbGpPWpGaD
Phentolamine—ADRA1B—central nervous system—Gilles de la Tourette syndrome	0.00776	0.0669	CbGeAlD
Phentolamine—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00771	0.00873	CbGpPWpGaD
Phentolamine—ADRA2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00769	0.0087	CbGpPWpGaD
Phentolamine—ADRA1D—central nervous system—Gilles de la Tourette syndrome	0.00759	0.0654	CbGeAlD
Phentolamine—ADRA2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00735	0.00832	CbGpPWpGaD
Phentolamine—ADRA1D—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00733	0.00829	CbGpPWpGaD
Phentolamine—ADRA1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00724	0.00819	CbGpPWpGaD
Phentolamine—NISCH—brain—Gilles de la Tourette syndrome	0.00722	0.0622	CbGeAlD
Phentolamine—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00717	0.00811	CbGpPWpGaD
Phentolamine—SIGMAR1—midbrain—Gilles de la Tourette syndrome	0.00669	0.0576	CbGeAlD
Phentolamine—ADRA2B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00662	0.00748	CbGpPWpGaD
Phentolamine—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00643	0.00727	CbGpPWpGaD
Phentolamine—ADRA2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00618	0.00699	CbGpPWpGaD
Phentolamine—ADRA1B—brain—Gilles de la Tourette syndrome	0.00616	0.0531	CbGeAlD
Phentolamine—ADRA1D—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00611	0.00692	CbGpPWpGaD
Phentolamine—ADRA1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00608	0.00688	CbGpPWpGaD
Phentolamine—ADRA1D—brain—Gilles de la Tourette syndrome	0.00603	0.0519	CbGeAlD
Phentolamine—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00597	0.00676	CbGpPWpGaD
Phentolamine—ADRA1D—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00594	0.00671	CbGpPWpGaD
Phentolamine—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0054	0.00611	CbGpPWpGaD
Phentolamine—ADRA2C—midbrain—Gilles de la Tourette syndrome	0.00525	0.0452	CbGeAlD
Phentolamine—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00502	0.00568	CbGpPWpGaD
Phentolamine—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.00453	0.039	CbGeAlD
Phentolamine—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.00436	0.0376	CbGeAlD
Phentolamine—ADRA2C—nervous system—Gilles de la Tourette syndrome	0.00432	0.0372	CbGeAlD
Phentolamine—SIGMAR1—brain—Gilles de la Tourette syndrome	0.0042	0.0362	CbGeAlD
Phentolamine—ADRA2A—midbrain—Gilles de la Tourette syndrome	0.00419	0.0361	CbGeAlD
Phentolamine—ADRA2C—central nervous system—Gilles de la Tourette syndrome	0.00416	0.0358	CbGeAlD
Phentolamine—ADRA1D—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00387	0.00438	CbGpPWpGaD
Phentolamine—ADRA1A—brain—Gilles de la Tourette syndrome	0.00346	0.0298	CbGeAlD
Phentolamine—ADRA2A—nervous system—Gilles de la Tourette syndrome	0.00344	0.0297	CbGeAlD
Phentolamine—ADRA2A—central nervous system—Gilles de la Tourette syndrome	0.00332	0.0286	CbGeAlD
Phentolamine—ADRA2C—brain—Gilles de la Tourette syndrome	0.0033	0.0284	CbGeAlD
Phentolamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00266	0.003	CbGpPWpGaD
Phentolamine—ADRA2A—brain—Gilles de la Tourette syndrome	0.00263	0.0227	CbGeAlD
Phentolamine—ADRA2B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00258	0.00292	CbGpPWpGaD
Phentolamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00258	0.00292	CbGpPWpGaD
Phentolamine—ADRA2B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00251	0.00284	CbGpPWpGaD
Phentolamine—ADRA2C—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00241	0.00273	CbGpPWpGaD
Phentolamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0024	0.00272	CbGpPWpGaD
Phentolamine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0024	0.00271	CbGpPWpGaD
Phentolamine—ADRA2C—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00234	0.00265	CbGpPWpGaD
Phentolamine—ADRA2B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00234	0.00264	CbGpPWpGaD
Phentolamine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00233	0.00263	CbGpPWpGaD
Phentolamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00228	0.00257	CbGpPWpGaD
Phentolamine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00224	0.00253	CbGpPWpGaD
Phentolamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00221	0.0025	CbGpPWpGaD
Phentolamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0022	0.00249	CbGpPWpGaD
Phentolamine—ADRA2C—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00218	0.00247	CbGpPWpGaD
Phentolamine—ADRA1D—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00218	0.00246	CbGpPWpGaD
Phentolamine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00217	0.00246	CbGpPWpGaD
Phentolamine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00217	0.00245	CbGpPWpGaD
Phentolamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00214	0.00242	CbGpPWpGaD
Phentolamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00206	0.00233	CbGpPWpGaD
Phentolamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00205	0.00232	CbGpPWpGaD
Phentolamine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00203	0.00229	CbGpPWpGaD
Phentolamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00199	0.00226	CbGpPWpGaD
Phentolamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00199	0.00226	CbGpPWpGaD
Phentolamine—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00196	0.00222	CbGpPWpGaD
Phentolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00196	0.00222	CbGpPWpGaD
Phentolamine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00195	0.0022	CbGpPWpGaD
Phentolamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00192	0.00217	CbGpPWpGaD
Phentolamine—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.0019	0.00215	CbGpPWpGaD
Phentolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0019	0.00215	CbGpPWpGaD
Phentolamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00189	0.00214	CbGpPWpGaD
Phentolamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00186	0.00211	CbGpPWpGaD
Phentolamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00186	0.0021	CbGpPWpGaD
Phentolamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00183	0.00207	CbGpPWpGaD
Phentolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00182	0.00206	CbGpPWpGaD
Phentolamine—ADRA1B—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00181	0.00204	CbGpPWpGaD
Phentolamine—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00177	0.00201	CbGpPWpGaD
Phentolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00177	0.002	CbGpPWpGaD
Phentolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00177	0.002	CbGpPWpGaD
Phentolamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00174	0.00196	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00173	0.00196	CbGpPWpGaD
Phentolamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00171	0.00193	CbGpPWpGaD
Phentolamine—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00168	0.0019	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00168	0.0019	CbGpPWpGaD
Phentolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00168	0.0019	CbGpPWpGaD
Phentolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00165	0.00186	CbGpPWpGaD
Phentolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00163	0.00184	CbGpPWpGaD
Phentolamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00162	0.00183	CbGpPWpGaD
Phentolamine—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.0016	0.00182	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00157	0.00177	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00156	0.00177	CbGpPWpGaD
Phentolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00156	0.00176	CbGpPWpGaD
Phentolamine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00152	0.00172	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00152	0.00172	CbGpPWpGaD
Phentolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00152	0.00172	CbGpPWpGaD
Phentolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00151	0.00171	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00146	0.00165	CbGpPWpGaD
Phentolamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00144	0.00163	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00144	0.00163	CbGpPWpGaD
Phentolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00144	0.00162	CbGpPWpGaD
Phentolamine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00142	0.00161	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00142	0.0016	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00141	0.0016	CbGpPWpGaD
Phentolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00141	0.00159	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—HDC—Gilles de la Tourette syndrome	0.0014	0.00159	CbGpPWpGaD
Phentolamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0014	0.00158	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0014	0.00158	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00132	0.0015	CbGpPWpGaD
Phentolamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.0013	0.00147	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0013	0.00147	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00128	0.00145	CbGpPWpGaD
Phentolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00124	0.0014	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00124	0.0014	CbGpPWpGaD
Phentolamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00122	0.00138	CbGpPWpGaD
Phentolamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.0012	0.00135	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00119	0.00134	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00116	0.00131	CbGpPWpGaD
Phentolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00115	0.0013	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00115	0.0013	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	0.00114	0.00129	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0011	0.00124	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00107	0.00121	CbGpPWpGaD
Phentolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00106	0.0012	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000991	0.00112	CbGpPWpGaD
Phentolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000987	0.00112	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000979	0.00111	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000951	0.00108	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000926	0.00105	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000911	0.00103	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000889	0.00101	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000886	0.001	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000884	0.001	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000863	0.000977	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000858	0.000971	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000826	0.000934	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000813	0.00092	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000809	0.000915	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000804	0.00091	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000803	0.000908	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000802	0.000907	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.0008	0.000905	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000789	0.000893	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000779	0.000882	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000752	0.000851	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00075	0.000848	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000747	0.000845	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000738	0.000835	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000735	0.000832	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000728	0.000824	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000726	0.000821	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000722	0.000817	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000717	0.000811	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000701	0.000793	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000678	0.000767	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000671	0.000759	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000668	0.000755	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000656	0.000742	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000653	0.000739	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000651	0.000737	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000636	0.00072	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00062	0.000702	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000609	0.000689	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000607	0.000686	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000593	0.000671	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000591	0.000669	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000563	0.000637	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00056	0.000634	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000551	0.000623	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000525	0.000594	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000523	0.000592	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000515	0.000582	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00051	0.000577	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000509	0.000575	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000475	0.000537	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000475	0.000537	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000474	0.000537	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000468	0.000529	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00046	0.000521	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000457	0.000517	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000443	0.000501	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000436	0.000493	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00043	0.000487	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000429	0.000485	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000425	0.000481	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000423	0.000479	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000415	0.00047	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000401	0.000453	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000394	0.000446	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000387	0.000438	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000386	0.000436	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000376	0.000425	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00036	0.000407	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00035	0.000396	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000349	0.000395	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000333	0.000376	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000325	0.000368	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.0003	0.00034	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000281	0.000317	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000276	0.000312	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000245	0.000278	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000228	0.000258	CbGpPWpGaD
